NCT01214759View on ClinicalTrials.gov

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

PHASE4CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

August 31, 2015

Conditions

HIV

Interventions

DRUG

Truvada

Tenofovir 200mg/emtricitabine 300mg once a day

DRUG

Raltegravir

Raltegravir 400mg twice a day

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER